Who is sponsoring NCT05254899?

NCT05254899 is sponsored by Chinese Academy of Medical Sciences.

What drugs are being tested in NCT05254899?

Interventions in NCT05254899: Anti-PD-1 monoclonal antibody, Pegaspargase, Gemcitabine, Oxaliplatin, Involved site radiotherapy.

What condition does NCT05254899 study?

NCT05254899 studies Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer.

Is NCT05254899 still recruiting?

NCT05254899 is currently status unknown. Last updated 24 February 2022.

Last reviewed 2022-02-24 · How we verify

NCT05254899

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

Status unknown Phase 2 Last updated 24 February 2022

What this trial tests

Phase 2 trial testing Anti-PD-1 monoclonal antibody in Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type in 54 participants. Status unknown.

Timeline

1 October 2021

Primary endpoint
30 September 2022

30 September 2024

Quick facts

Lead sponsor	Chinese Academy of Medical Sciences
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	1 October 2021
Primary completion	30 September 2022
Estimated completion	30 September 2024
Sites	1 location across China

Drugs / interventions tested

Anti-PD-1 monoclonal antibody — full drug profile →
Pegaspargase — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →
Oxaliplatin (Oxaliplatin) — full drug profile →
Involved site radiotherapy

Conditions studied

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type — all drugs for Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type →
Early-stage — all drugs for Early-stage →
High-Risk Cancer — all drugs for High-Risk Cancer →

Sponsor

Chinese Academy of Medical Sciences — full company profile →

Who can join

Adults 18 to 70, any sex, with Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type or Early-stage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of inductive Anti-PD-1+P-GEMOX treatment followed by radiotherapy and concurrent Anti-PD-1 antibody in early-stage high-risk extranodal NK/T cell lymphoma, nasal type

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Novel target and treatment agents for natural killer/T-cell lymphoma.
Tian XP, Cao Y, Cai J, Zhang YC, et al · · 2023 · cited 19× · PMID 37480137 · DOI 10.1186/s13045-023-01483-9
Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy.
Douka S, Papamoschou V, Raimo M, Mastrobattista E, et al · · 2024 · cited 6× · PMID 39339180 · DOI 10.3390/pharmaceutics16091143
Optimizing the combination of chemotherapeutic drugs along with radiotherapy for extranodal NK/T-cell lymphoma.
Luo F, Zhong QZ, Liu X, Hou XR, et al · · 2024 · cited 1× · PMID 39399411 · DOI 10.1177/17588359241285981
Immunotherapy in NK/T-Cell Lymphoma: Mechanisms, Clinical Evidence, Resistance, and Emerging Multimodal Strategies.
Zhang Q, Wang X. · · 2026 · PMID 42122154 · DOI 10.3390/cancers18091358
Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies.
Li T, Wang C, Xiao Q, Zhang X, et al · · 2026 · PMID 41741411 · DOI 10.1038/s41408-026-01453-7
Antibody-Based Therapies for Peripheral T-Cell Lymphoma.
Shafagati N, Paul S, Rozati S, Sterling CH. · · 2024 · PMID 39456582 · DOI 10.3390/cancers16203489

Verify or expand the search:

Other trials of Anti-PD-1 monoclonal antibody

Trials testing the same drug.

NCT07365592 — Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC · Phase 1, PHASE2 · not yet recruiting
NCT06603844 — First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. · Phase 1, PHASE2 · recruiting
NCT06556199 — A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primar · Phase 1, PHASE2 · recruiting
NCT06728657 — Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma · Phase 2 · suspended
NCT06349044 — A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed · NA · recruiting

Other Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05254899 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
Last refreshed: 24 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05254899.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing